← Insight Molecular Diagnostics Inc. (IMDX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Insight Molecular Diagnostics Inc. (IMDX)
In Vitro & In Vivo Diagnostic Substances · market cap $124M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Insight Molecular Diagnostics Inc. (IMDX) is a ~$164M market-cap diagnostic and specialty pharmaceutical company with a diverse pipeline anchored by 99mTc-MIP-1404, a PSMA-targeted imaging agent in Phase 3 for prostate cancer. The company posted a positive data readout on June 16, 2026, and carries approximately $28.2M in cash, representing roughly 11 months of runway at current burn rates. Revenue remains minimal (~$4M in 2025) against persistent net losses exceeding $50M annually.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 99mTc-MIP-1404 Injection | Phase 3 | Prostate Cancer |
| Drug: 99mTc-MIP-1404 | Phase 2 | Prostate Cancer |
| UltratraceTM Iobenguane I 131 Imaging | Phase 2 | Neuroblastoma |
| NeuVax vaccine | Phase 2 | Breast Cancer |
| Iodofiltic acid I 123 | Phase 2 | Acute Coronary Syndrome |
| Ultratrace Iobenguane (MIBG) I 131 | Phase 2 | Pheochromocytoma |
| Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free | Phase 3 | Dry Eye |
Price & technical context
3-month
-37.1%
6-month
-5.6%
12-month
+7.9%
52-wk range
$2.55–$8.48
vs 50-day MA
-15.7%
vs 200-day MA
-30.1%
Realized vol
109.8%
Max drawdown
-69.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMDX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.